With the intensification of population aging in China and changes in residents' dietary structure, the cardiovascular disease population in China is growing rapidly, and the demand for cardiovascular diagnosis and treatment continues to increase. Data from the National Bureau of Statistics of China show that by 2020, the elderly population aged 65 and above had risen to 190 million, accounting for 13.5% of the total population. It is expected that the elderly population will continue to grow in the future. According to the 'China Cardiovascular Health and Disease Report 2021', the number of current cardiovascular patients in China was 330 million in 2019, with 245 million suffering from hypertension. The trend of population aging and changes in the disease spectrum will continuously expand China's demand in the field of vascular interventional surgical instruments, promoting the development of the vascular interventional surgical instrument industry.
Based on our long-term attention to the market for vascular disease treatment instruments, Frost & Sullivan hereby releases the 'Vascular Disease Treatment Instrument Market Research Report'.
